Charité Research Organisation (CRO) supports pharmaceutical, biopharmaceutical, nutrition and health technology companies to develop and evaluate their products. CRO primarily supports its customers with early clinical development activities. This includes the design and conduct of First Time in Human, Phase I and Proof of Concept clinical studies.
Based in Berlin, CRO was founded in 2005 as a daughter company of Charité – Universitätsmedizin Berlin. CRO operates a fully equipped Phase I clinical research facility, allowing it to undertake both in-patient and out-patient studies in healthy volunteers and patients.
By working with Charité clinicians and opinion leaders, CRO is able to seamlessly integrate leading clinical expertise, imaging, diagnostic and biomarker capabilities into early clinical studies. Starting with support for conceptualisation, design and regulatory submission of studies, this level of expert input is of great value. It allows CRO’s customers to maximise the effectiveness of their initial clinical studies and learn more about their product early on. This in turn helps them to make informed decisions about further development options and shape future clinical studies.
ManagementProf. Dr. med. Frank Wagner
(Chief Executive Officer &
Chief Scientific Officer)
Year of establishment2005
Business activityConsultancy, First Time in Human,
Phase I, Proof of Concept